Peptides Similar to Aleniglipron
Compare Aleniglipron with related peptides and alternatives
📌TL;DR
- •3 similar peptides identified
- •Orforglipron: Very high - Both are oral non-peptide small molecule GLP-1 agonists
- •Semaglutide: Moderate - Both target GLP-1 receptor but via different molecular approaches
Quick Comparison
| Peptide | Similarity | Key Differences |
|---|---|---|
| Aleniglipron (current) | - | - |
| Orforglipron | Very high - Both are oral non-peptide small molecule GLP-1 agonists | Orforglipron is more advanced (Phase 3). Aleniglipron showed 11.3-15.3% weight loss in Phase 2b. |
| Semaglutide | Moderate - Both target GLP-1 receptor but via different molecular approaches | Semaglutide is a peptide requiring injection or special oral formulation. Aleniglipron is a convenient oral small molecule. |
| Tirzepatide | Low-moderate - Both target metabolic disease but different mechanisms | Tirzepatide is injectable dual GLP-1/GIP. Aleniglipron is oral GLP-1 only. |
OrforglipronVery high - Both are oral non-peptide small molecule GLP-1 agonists
Differences
Orforglipron is more advanced (Phase 3). Aleniglipron showed 11.3-15.3% weight loss in Phase 2b.
Advantages
More advanced development, larger dataset, Eli Lilly resources
Disadvantages
Aleniglipron 240 mg dose may be competitive at 15.3% weight loss
SemaglutideModerate - Both target GLP-1 receptor but via different molecular approaches
Differences
Semaglutide is a peptide requiring injection or special oral formulation. Aleniglipron is a convenient oral small molecule.
Advantages
FDA-approved, proven CV benefit, extensive data, multiple formulations
Disadvantages
Primary formulation requires injection
TirzepatideLow-moderate - Both target metabolic disease but different mechanisms
Differences
Tirzepatide is injectable dual GLP-1/GIP. Aleniglipron is oral GLP-1 only.
Advantages
Greater weight loss (up to 22.5%), FDA-approved
Disadvantages
Requires weekly injection
Agents Related to Aleniglipron#
Aleniglipron competes in the oral small molecule GLP-1 agonist space, primarily against orforglipron. Both could transform obesity treatment by removing injection barriers.
| Feature | Aleniglipron | Orforglipron | Semaglutide | Tirzepatide |
|---|---|---|---|---|
| Type | Small molecule | Small molecule | Peptide | Peptide |
| Route | Oral daily | Oral daily | SC weekly / oral | SC weekly |
| Weight loss | 11.3-15.3% | ~14.7% | 14.9% | 15-22.5% |
| Regulatory | Phase 2b | Phase 3 | Approved | Approved |
Comparison Context#
Aleniglipron belongs to the Metabolic category of research peptides. Comparing Aleniglipron with related compounds helps researchers understand its relative positioning in the therapeutic landscape. Each compound has distinct advantages and limitations that should be considered based on the specific research question or clinical need.
Detailed Comparisons#
The following peptides and compounds are most closely related to Aleniglipron in mechanism, indication, or therapeutic category:
Aleniglipron vs Orforglipron#
Similarity: Very high - Both are oral non-peptide small molecule GLP-1 agonists
Key Differences: Orforglipron is more advanced (Phase 3). Aleniglipron showed 11.3-15.3% weight loss in Phase 2b.
Advantages of Orforglipron: More advanced development, larger dataset, Eli Lilly resources
Disadvantages of Orforglipron: Aleniglipron 240 mg dose may be competitive at 15.3% weight loss
Researchers choosing between Aleniglipron and Orforglipron should consider the development stage, available evidence, and specific research objectives when making their selection.
Aleniglipron vs Semaglutide#
Similarity: Moderate - Both target GLP-1 receptor but via different molecular approaches
Key Differences: Semaglutide is a peptide requiring injection or special oral formulation. Aleniglipron is a convenient oral small molecule.
Advantages of Semaglutide: FDA-approved, proven CV benefit, extensive data, multiple formulations
Disadvantages of Semaglutide: Primary formulation requires injection
Researchers choosing between Aleniglipron and Semaglutide should consider the development stage, available evidence, and specific research objectives when making their selection.
Aleniglipron vs Tirzepatide#
Similarity: Low-moderate - Both target metabolic disease but different mechanisms
Key Differences: Tirzepatide is injectable dual GLP-1/GIP. Aleniglipron is oral GLP-1 only.
Advantages of Tirzepatide: Greater weight loss (up to 22.5%), FDA-approved
Disadvantages of Tirzepatide: Requires weekly injection
Researchers choosing between Aleniglipron and Tirzepatide should consider the development stage, available evidence, and specific research objectives when making their selection.
Related Reading#
Frequently Asked Questions About Aleniglipron
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer